Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
An Open-label, Single Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labelled AMG 706 (Motesanib) Followed by Extended Treatment With Motesanib in Patients With Advanced Solid Tumors
In order for a tumour to grow and spread to other parts of the body, it needs to have a blood supply. Certain proteins in the body, called cytokines or growth factors, have been shown to cause the growth of new blood vessels that supply tumours and therefore help the tumour to grow and spread. Motesanib (AMG 706) prevents these proteins from working, and may help to prevent the growth of tumours.
In the first part of this study, we will look at the way your body absorbs this drug into your blood, how your body changes and breaks down the drug, and then how the drug leaves your body in your urine and faeces.
In order to provide potential treatment benefit for the subjects who participated in the first part of the study, the second part of the study will allow subjects to continue on motesanib (AMG 706) treatment. The estimated length of this part of the study is unknown, and dependent on how subjects respond to motesanib (AMG 706).
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subjects with a pathologically documented and definitively diagnosed advanced solid tumor(excluding tumors that may significantly interfere with the absorption, metabolism, or excretion of the test article, such as primary or metastatic liver tumor with approximately >50% of liver tissue involvement) that is refractory to standard treatment or for which no curative therapy is available
- Eastern Cooperative Oncology Group performance status of 0-1
- Man or woman (male or female), age > 18 years
- Ability to understand and sign an Independent Ethics Committee (IEC) Approved informed
- Subjects must also fulfil Haematological, Renal, Hepatic and Coagulation criteria (not listed)
Exclusion Criteria:
- Acute disease state (e.g. nausea, vomiting, fever, diarrhea) within 7 days of Day 1
- History of documented arterial or venous thrombosis within 1 year of Day 1
- History of bleeding diathesis or bleeding within 14 days of Day 1, or hypercoagulopathy syndrome
- History of life-threatening ventricular arrhythmia (e.g. sustained ventricular tachycardia)
- History of pulmonary hemorrhage or gross hemoptysis (1/2 teaspoon of bright red blood or more) within 6 months of Day 1
- Central nervous system metastases (exception: subjects with treated, asymptomatic central nervous system metastases, those who have been clinically stable in the judgment of the investigator and off steroids for at least 30 days before Day 1 are eligible)
- Subjects with non-small cell lung cancer (NSCLC)
- Subjects with head and neck cancer
- Subjects with ovarian cancer
- Subjects with large central (located adjacent to or within the hilum or mediastinum) tumor lesions ≥ 3 cm, regardless of histology
- Uncontrolled hypertension: average systolic blood pressure > 150 mm Hg or average diastolic blood pressure > 90 mm Hg (average blood pressure of the three separate blood pressure values measured within 10 minutes during screening)
- Systemic chemotherapy within 28 days of Day 1
- Radiotherapy within 28 days of Day 1 or within 14 days of Day 1 for peripheral lesions
- Experimental or approved antibody therapy within 6 weeks before Day 1
- Concurrent or prior (within 4 weeks prior to Day 1 of 5 half-lives of the medication which ever is longer) treatment with potent CYP3A inducers, including but not limited to : phenytoin, carbamazepine, rifampicin, phenobarbital and St John's Wort
- Concurrent or prior (within 2 weeks prior to Day 1 or 5 half-lives of the medication which ever is longer) treatment with potent CYP3A inhibitors, including but not limited to: ketoconazole, itraconazole, fluconazole, clarithromycin, erythromycin, cyclosporine, tacrolimus, nefazodone and/or HIV protease inhibitors
- Concurrent or prior (within 2 weeks prior to Day 1) consumption of grapefruit (i.e. whole fruit or fruit juice)
- Subjects who as a result of gastrointestinal surgeries (including cholecystectomy) or a medical condition (e.g. constipation, cholecystitis / cholelithiasis) that will significantly alter the absorption, metabolism or excretion of motesanib.
- Subjects with irregular bowel habits (more than 3/day or less than 1 every 2 days).
- Subjects who will not refrain from taking herbal/ complementary therapies (which have the potential to alter the absorption, metabolism, or excretion of the [14C]-AMG 706) for 7 days before first dosing, and for the duration of the ADME part of the study.
- Concurrent immune modulators such as cyclosporine and tacrolimus
- Any anti-coagulation therapy within 7 days prior to Day 1
- Subjects whose occupation requires exposure to radiation or monitoring for radiation exposure
- Clinically significant cardiac disease within 12 months of study Day 1, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or ongoing arrhythmias requiring medication
- Major surgery (that which requires general anesthesia) within 28 days or minor surgery within 14 days of Day 1
- Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures
- History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with study participation or investigational product administration or may interfere with the interpretation of the study results
- Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection or any co-morbid disease that would increase risk of toxicity
- Any subject not consenting to use adequate contraceptive precautions (eg, hormonal, barrier or abstinence) during the course of the study and for 6 months after the last treatment
- Female subjects who have a positive pregnancy test at screening or on Day-1
- Female subjects who are breastfeeding or plan to breastfeed during the study or within 6 months after the last administration of the investigational product
- Participation in a therapeutic clinical trial within 30 days of Day1
- Subject is unwilling or unable to comply with the study requirements
- Subject has a known sensitivity to any of the products to be administered over the course of the study (e.g. known hypersensitivity to study medication motesanib)
- Subjects with a history of gall bladder and bile duct disease
- Subjects with Gilberts syndrome
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:あ
|
Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of [14C]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit.
Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
---|
Profile and identification of metabolites of [14C]-AMG 706 in plasma, urine, and faeces
|
Pharmacokinetics of total radioactivity in plasma and whole blood
|
The mass balance of [14C]-AMG 706 (as the percentage of the dose administered) in urine and faeces
|
二次結果の測定
結果測定 |
---|
• Measure the area under the plasma concentration curve versus time of AMG 706, as well as determine half-life and time of maximum concentration of AMG 706.
|
The subject incidences of serious adverse events, adverse events, and clinically significant changes in vital signs and clinical laboratory tests
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
進行性固形腫瘍の臨床試験
-
Advanced Bionics完了重度から重度の難聴 | Advanced Bionics HiResolution™ Bionic Ear System の成人ユーザーの割合アメリカ
-
QIAGEN Gaithersburg, Inc完了呼吸器合胞体ウイルス感染症 | インフルエンザA | ライノウイルス | インフルエンザB | QIAGEN ResPlex II Advanced Panel | ヒトパラインフルエンザウイルスによる感染症 1 | パラインフルエンザ2型 | パラインフルエンザ3型 | パラインフルエンザ4型 | ヒトメタニューモウイルス A/B | コクサッキーウイルス/エコーウイルス | アデノウイルス B型/C型/E型 | コロナウイルスサブタイプ 229E | コロナウイルス亜型NL63 | コロナウイルスサブタイプOC43 | コロナウイルスサブタイプ HKU1 | ヒトボカウイルス | Artus インフルエンザ A/B RT-PCR 検査アメリカ
-
Extremity Medical募集変形性関節症 | 炎症性関節炎 | 手根管症候群 (CTS) | 外傷性関節炎後 | スカホルネート高度崩壊 (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | 舟状骨、台形、および台形高度崩壊 (STTAC) | 成人のキーンボック病 | ラジアルマルニオン | 尺骨転座 | 舟状骨癒合不全高度崩壊 (SNAC)アメリカ
-
AstraZeneca募集Adv Solid Malig - H&N SCC、ATM Pro / Def NSCLC、胃がん、乳がん、卵巣がんスペイン, アメリカ, ベルギー, イギリス, フランス, ハンガリー, カナダ, 大韓民国, オーストラリア
AMG 706の臨床試験
-
Gedeon Richter Plc.募集
-
Amgen完了進行性固形腫瘍ベルギー, カナダ, オーストラリア, アメリカ, スペイン, ポーランド, フランス, ドイツ, 日本, イギリス
-
Amgen終了しました再発/難治性急性骨髄性白血病 (AML)アメリカ, 大韓民国, オーストラリア, 日本, ドイツ, カナダ
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)完了